-
Overview of clinical projects of cancer cell immunotherapy: over 2000 pipelines CAR-...
Time of Update: 2021-06-23
, IQVIA, a world-renowned medical industry consulting company, and the non-profit organization Cancer Research Institute (CRI) published an analyst report titled The clinical pipeline for cancer cell therapies in Nature Reviews Drug Discovery
-
The complete remission rate of refractory patients exceeds 30% CD37 targeted ADC combination Phase 2...
Time of Update: 2021-06-22
of relapsed/refractory (R/R) diffuse Positive results were obtained in a phase 2 clinical trial of large B-cell lymphoma (DLBCL) . The trial results showed that the combination therapy achieved
-
What are the important developments of innovative therapies developed around p53 targets in the past 40 years?
Time of Update: 2021-06-22
detailed, innovative therapies around this target have not been born for more than 40 years . Among them, there are some scientific challenges .
</span
-
2021 EHA Big Coffee Interview Professor Cao Xinxin: Interpretation of Research Progress in Light Chain Amyloidosis
Time of Update: 2021-06-22
(PR) 21. 1%, and no remission (NR) 31. 1% . The median OS of patients with ≥VGPR at 1 month has not yet reached, while the median OS of patients with only PR or NR
-
The prognosis of AML with other gene mutations in different IDH mutation subgroups is different
Time of Update: 2021-06-22
Based on this, some researchers retrospectively analyzed the prognosis of newly diagnosed AML patients with IDH mutation who received IC treatment based on data from three prospective clinical trials of the French Acute Leukemia Association (ALFA) .
-
NSMB Xu Dong Group Reveals New Pathogenesis of Fanconi's Anemia
Time of Update: 2021-06-22
to cells and living organisms and is difficult to repair . The stagnation of replication forks caused by replication pressure is also the main source of cancer cell genome
-
EHA 2021: The latest results of clinical trials of CRISPR and Vertex for the treatment of hereditary hemoglobinopathy are positive
Time of Update: 2021-06-22
, and the oncolytic virus has entered the fast lane Yimai New Observation Click on the picture and register now June 16, 2021 /MedClub News/--A few days ago, CRISPR Therapeutics and Vertex Pharmaceuticals announced the Phase 1/2 clinical trial data
-
CD37 ADC combined with CD20 monoclonal antibody in the treatment of DLBCL, clinical results are positive, Yi Mai Meng broke the news
Time of Update: 2021-06-22
virus has entered the fast lane Yimai New Observation Click on the picture and register now June 16, 2021 /Healthcare News eMedClub News/--Recently, Debiopharm, a global biopharmaceutical company, announced the Phase 2 results of Narratuximab
-
[Lymphoma Microcourse 2021EHA] EP636 First-line Treatment of Ibrutinib in Patients with Chronic Lymphocytic Leukemia: 7-year follow-up of the RESONATE-2 study
Time of Update: 2021-06-22
Today I will mainly introduce an abstract on EHA in 2021: First-line treatment of Ibrutinib in patients with chronic lymphocytic leukemia: 7-year follow-up of the RESONATE-2 study .
-
EHA hot spot: A number of phase III studies of C5 complement inhibitor Crovalimab have entered the recruitment phase, and the research and development in China is synchronized with the global
Time of Update: 2021-06-22
At the 26th European Annual Conference on Blood (EHA) this year, crovalimab announced three important research designs, including two important phase III clinical trials (COMMODORE 1, COMMODORE) 2), and a study related to the burden of PNH disease (COMMODORE BoI).
-
Express delivery of potential "first-in-class" complement inhibitors to reach the phase 3 clinical endpoint, and submit a regulatory application this year
Time of Update: 2021-06-22
C1s protein inhibitor sutimlimab is a pivotal phase 3 clinical trial in the treatment of patients with cold agglutinin disease (CAD) It can quickly and continuously inhibit the hemolysis caused by C1 activation in CAD patients, and it can also
-
Best-in-class security!
Time of Update: 2021-06-22
Reddy Laboratories and Simcere Pharmaceuticals respectively, Prekin announced the targeting of BCMA CAR-T at the ASCO 2021 annual meeting The latest data of an unregistered clinical study conducted by Cell Injection in Henan Cancer Hospital.
-
Nature Medicine blockbuster article: The new CRISPR-Cas9 technology can realize the replacement of complete endogenous genes and successfully treat the β-thalassemia mouse model
Time of Update: 2021-06-22
to the clinical stage . Headquartered in Basel, Switzerland, Lonza is an excellent partner in the global pharmaceutical, biotechnology and nutrition markets <span
-
2021 EHA Eltropapax shows considerable efficacy and safety in the treatment of aplastic anemia
Time of Update: 2021-06-22
>. No new safety signals were observed in this study . Abstract S157: Based on the data from the French RIME Observatory to evaluate the effect
-
[EHA hot spot] FcRH5/CD3 bispecific antibody Cevostamab may bring new hope to RRMM patients
Time of Update: 2021-06-22
membrane protein containing an Ig domain and is only expressed in the B cell lineage 2-4 . The FcRH5 gene is located near the chromosomal breakpoint in 1q21. 4. <br
-
2021 EHA Voice of China Professor Zhou Daobin's team new progress: R2-MTX regimen for the treatment of newly diagnosed PCNSL
Time of Update: 2021-06-22
regimen is treated for 6 cycles, followed by lenalidomide maintenance treatment (25 mg daily, 1-21 days, 28 days as a cycle), for a maximum of 2 years . In the phase I study, dose
-
Express all patients in remission, CRISPR gene editing therapy shows "cure" potential
Time of Update: 2021-06-22
Through CTX001 treatment, HbF levels can be increased, it is possible to alleviate the blood transfusion needs of TDT patients, and reduce the pain and debilitating vascular occlusive crisis of SCD patients .
-
Blood: sutimlimab therapy improves severe hemolytic anemia in cold agglutinin disease
Time of Update: 2021-06-21
Bernd Jilma of the Medical University of Vienna, said: "The drug is well tolerated, resulting in a clinically significant increase in hemoglobin levels, and eliminating the need for blood transfusions, even for patients who have failed many previous treatments.
-
JCO: Final analysis results of Ixazomi combined with lenalidomide + dexamethasone in the treatment of relapsed or refractory multiple myeloma (RRMM): Phase III clinical study TOURMALINE-MM1
Time of Update: 2021-06-21
The progression-free survival (PFS) benefit of Ixazomib-Rd in the treatment of relapsed or refractory multiple myeloma (RRMM) did not translate into the benefit of OS .
-
Leukemia: iFCG chemotherapy regimen for the treatment of chronic lymphocytic leukemia with IGHV mutation and without TP53 mutation
Time of Update: 2021-06-21
Response to treatmentResponse to treatmentAll in all, the results of the study revealed that only 3 cycles of iFCG chemotherapy is an effective time-limited treatment for CLL patients with IGHV mutations and no del(17p)/TP53 mutations .
